Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 19 results.
User Information
Export Records
  1. 1.   Nanoparticle physicochemical properties determine the activation of intracellular complement
  2. Ilinskaya, Anna N.; Shah, Ankit; Enciso, Alan E.; Chan,King; Kaczmarczyk,Jan; Blonder,Josip; Simanek, Eric E.; Dobrovolskaia,Marina
  3. Nanomedicine : nanotechnology, biology, and medicine. 2019, APR; 17: 266-275.
  1. 2.   Toll-Like Receptor-Mediated Recognition of Nucleic Acid Nanoparticles (NANPs) in Human Primary Blood Cells
  2. Hong, Enping; Halman, Justin R; Shah, Ankit; Cedrone,Edward; Truong, Nguyen; Afonin, Kirill A; Dobrovolskaia,Marina
  3. Molecules (Basel, Switzerland). 2019, Mar 2; 24(6): pii: E1094.
  1. 3.   Acute physiological changes caused by complement activators and amphotericin B-containing liposomes in mice
  2. Orfi, Erik; Meszaros, Tamas; Hennies, Mark; Fulop, Tamas; Dezsi, Laszlo; Nardocci, Alexander; Rosivall, Laszlo; Hamar, Peter; Neun, Barry; Dobrovolskaia, Marina; Szebeni, Janos; Szenasi, Gabor
  3. International journal of nanomedicine. 2019, Feb 26; 14: 1563-1573.
  1. 4.   Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro
  2. Neun, Barry; Barenholz, Yechezkel; Szebeni, Janos; Dobrovolskaia, Marina
  3. Molecules. 2018, Jul 12; 23(7): pii: E1700.
  1. 5.   High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems
  2. Manimala, J. C.; Roach, T. A.; Li, Z. T.; Gildersleeve, J. C.
  3. Glycobiology. 2007, Aug; 17(8): 17C-23C.
  1. 6.   Brain-derived neurotrophic factor (BDNF) is required for the enhancement of hippocampal neurogenesis following environmental enrichment
  2. Rossi, C.; Angelucci, A.; Costantin, L.; Braschi, C.; Mazzantini, M.; Babbini, F.; Fabbri, M. E.; Tessarollo, L.; Maffei, L.; Berardi, N.; Caleo, M.
  3. European Journal of Neuroscience. 2006, Oct; 24(7): 1850-1856.
  1. 7.   Injectable formulation of disodium 1-[2-(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO), an ultrafast nitric oxide donor prodrug
  2. Waterhouse, D. J.; Saavedra, J. E.; Davies, K. M.; Citro, M. L.; Xu, X.; Powell, D. A.; Grimes, G. J.; Potti, G. K.; Keefer, L. K.
  3. Journal of Pharmaceutical Sciences. 2006, JAN; 95(1): 108-115.
  1. 8.   Phase I trial of temozolomide plus O-6-benzylguanine for patients with recurrent or progressive malignant glioma
  2. Quinn, J. A.; Desjardins, A.; Weingart, J.; Brem, H.; Dolan, M. E.; Delaney, S. M.; Vredenburgh, J.; Rich, J.; Friedman, A. H.; Reardon, D. A.; Sampson, J. H.; Pegg, A. E.; Moschel, R. C.; Birch, R.; McLendon, R. E.; Provenzale, J. M.; Gururangan, S.; Dancey, J. E.; Maxwell, J.; Tourt-Uhlig, S.; Herndon, J. E.; Bigner, D. D.; Friedman, H. S.
  3. Journal of Clinical Oncology. 2005, OCT 1; 23(28): 7178-7187.
  1. 9.   Limiting dilution analysis of interleukin-2 producing helper T-cell frequencies as a tool in allogeneic hematopoietic cell transplantation
  2. Petersen, S. L.; Sidorov, I. A.; Russell, C. A.; Dickmeiss, E.; Vindelov, L. L.
  3. Transplantation. 2005, SEP 15; 80(5): 573-581.
  1. 10.   7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr(308) but not Ser(473) phosphorylation: A basis for decreased insulin-stimulated glucose transport
  2. Kondapaka, S. B.; Zarnowski, M. J.; Yver, D. R.; Sausville, E. A.; Cushman, S. W.
  3. Clinical Cancer Research. 2004, NOV 1; 10(21): 7192-7198.
  1. 11.   Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction
  2. Walsh, T. J.; Shoham, S.; Petraitiene, R.; Sein, T.; Schaufele, R.; Kelaher, A.; Murray, H.; Mya-San, C.; Bacher, J.; Petraitis, V.
  3. Journal of Clinical Microbiology. 2004, OCT; 42(10): 4744-4748.
  1. 12.   SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2: Efficacy evaluations
  2. Alley, M. C.; Hollingshead, M. G.; Pacula-Cox, C. M.; W, W. R.; Hartley, J. A.; Howard, P. W.; Gregson, S. J.; Thurston, D. E.; Sausville, E. A.
  3. Cancer Research. 2004, SEP 15; 64(18): 6700-6706.
  1. 13.   Host conditioning is a primary determinant in modulating the effect of IL-7 on murine graft-versus-host disease
  2. Gendelman, M.; Hecht, T.; Logan, B.; Vodanovic-Jankovic, S.; Komorowski, R.; Drobyski, W. R.
  3. Journal of Immunology. 2004 172(5): 3328-3336.
  1. 14.   Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: A randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma
  2. Smith, J. W.; Kurt, R. A.; Baher, A. G.; Denman, S.; Justice, L.; Doran, T.; Gilbert, T.; Alvord, W. G.; Urba, W. J.
  3. Journal of Immunotherapy. 2003 26(2): 130-138.
  1. 15.   Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas
  2. Weyerbrock, A.; Walbridge, S.; Pluta, R. M.; Saavedra, J. E.; Keefer, L. K.; Oldfield, E. H.
  3. Journal of Neurosurgery. 2003 99(4): 728-737.
  1. 16.   Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the national cancer institute's anticancer drug screen
  2. Grem, J. L.; Danenberg, K. D.; Behan, K.; Parr, A.; Young, L.; Danenberg, P. V.; Nguyen, D.; Drake, J.; Monks, A.; Allegra, C. J.
  3. Clinical Cancer Research. 2001 7(4): 999-1009.
  1. 17.   Phase I trial of recombinant immunotoxin anti-Tac(Fv)PE38 (LMB-2) in patients with hematologic malignancies
  2. Kreitman, R. J.; Wilson, W. H.; White, J. D.; Stetler-Stevenson, M.; Jaffe, E. S.; Giardina, S.; Waldmann, T. A.; Pastan, I.
  3. Journal of Clinical Oncology. 2000 18(8): 1622-1636.
  1. 18.   Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection
  2. Walker, R. E.; Bechtel, C. M.; Natarajan, V.; Baseler, M.; Hege, K. M.; Metcalf, J. A.; Stevens, R.; Hazen, A.; Blaese, R. M.; Chen, C. C.; Leitman, S. F.; Palensky, J.; Wittes, J.; Davey, R. T.; Falloon, J.; Polis, M. A.; Kovacs, J. A.; Broad, D. F.; Levine, B. L.; Roberts, M. R.; Masur, H.; Lane, H. C.
  3. Blood. 2000 96(2): 467-474.
  1. 19.   BDNF promotes the regenerative sprouting, but not survival, of injured serotonergic axons in the adult rat brain
  2. Mamounas, L. A.; Altar, C. A.; Blue, M. E.; Kaplan, D. R.; Tessarollo, L.; Lyons, W. E.
  3. Journal of Neuroscience. 2000 20(2): 771-782.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel